Epidemiology and survival outcomes in stages II and III cutaneous melanoma: a systematic review

Rachael Miller; Sophie Walker; Irene Shui; Agnes Brandtmüller; Kevin Cadwell; Emilie Scherrer

doi:10.2217/mmt-2019-0022

Epidemiology and survival outcomes in stages II and III cutaneous melanoma: a systematic review

Melanoma Manag. 2020 Mar 19;7(1):MMT39. doi: 10.2217/mmt-2019-0022.

Authors

Rachael Miller¹, Sophie Walker¹, Irene Shui², Agnes Brandtmüller³, Kevin Cadwell¹, Emilie Scherrer²

Affiliations

¹ PHMR Ltd, Berkeley Works, Berkley Grove, Camden Town, London, UK.
² Merck & Co., Inc., Kenilworth, NJ 07033, USA.
³ MSD: Pharma Hungary Ltd, Budapest, 1095, Hungary.

Abstract

Aim: Management of cutaneous melanoma (CM) is continually evolving with adjuvant treatment of earlier stage disease. The aim of this review was to identify published epidemiological data for stages II-III CM.

Materials & methods: Systematic searches of Medline and Embase were conducted to identify literature reporting country/region-specific incidence, prevalence, survival or mortality outcomes in stage II and/or III CM. Screening was carried out by two independent reviewers.

Results & conclusion: Of 41 publications, 14 described incidence outcomes (incidence rates per stage were only reported for US and Swedish studies), 33 reported survival or mortality outcomes and none reported prevalence data. This review summarizes relevant data from published literature and highlights an overall paucity of epidemiological data in stages II and III CM.

Keywords: adjuvant therapy; cancer; cutaneous melanoma; epidemiology; incidence; mortality; skin (melanoma); staging; survival.

Publication types

Review